Apr. 6 at 9:34 PM
$MYGN 🧬 Don’t sleep on the math here. Market Cap is <
$450M while 2026 Revenue guidance is
$860M–
$880M. That is a 0.5x P/S multiple in a sector where peers (EXAS, NEO, GH) trade at 2x–5x.
💎 The Bull Thesis:
• Profitability Pivot: 2026 Adj. EBITDA guide of
$37M–
$49M (up 40%+ YoY).
• MRD Catalyst: Just launched Precise MRD (breast cancer) in March. CLIA submissions in Q3 for renal/colorectal. This is the high-growth "Holy Grail" of oncology diagnostics.
• The CMS Tailwind: The 2.48% MA rate hike removes the "payer squeeze" risk. Healthy insurers = faster adoption and smoother reimbursement for GeneSight and MyRisk.
📊 Price Targets:
• Average Analyst PT (
$7.85): ~75% upside.
• High PT (
$10.00+): 120%+ upside.
• At 1.0x P/S (Still cheap!): ~
$9.50+ share price.
Shorts are betting on a legacy "testing" story, but the math says this is a profitable, AI-driven precision medicine powerhouse at a firesale price. 🚀
